Plant Compound 4-Nerolidylcatechol Targets Key Protein in Drug-Resistant Prostate Cancer
A natural compound from Piper umbellatum binds Derlin-1 to disrupt protein quality control in castration-resistant prostate cancer cells.
Summary
Castration-resistant prostate cancer (CRPC) is notoriously difficult to treat because cancer cells activate survival pathways that bypass androgen deprivation. Researchers investigated 4-Nerolidylcatechol (4-NC), a natural compound from the tropical plant Piper umbellatum, as a potential new weapon against CRPC. Using computer modeling and lab experiments, they found that 4-NC binds to Derlin-1, a protein that helps cancer cells manage cellular stress and survive. In PC-3 prostate cancer cells, 4-NC killed cancer cells at roughly half the concentration needed to harm normal cells, and it triggered oxidative stress, damaged mitochondria, and activated pathways that push cells toward self-destruction. These findings identify Derlin-1 as a new molecular target in CRPC and position 4-NC as a promising natural lead compound for future drug development.
Detailed Summary
Castration-resistant prostate cancer (CRPC) remains one of oncology's toughest challenges. When standard androgen-deprivation therapy fails, tumors activate alternative survival mechanisms — including chronic endoplasmic reticulum (ER) stress pathways — to keep proliferating. The ERAD (ER-associated degradation) pathway, and its central mediator Derlin-1, becomes essential for maintaining protein homeostasis in these stressed cancer cells, making it an attractive but underexplored therapeutic target.
Researchers from Universidade Federal de Uberlândia investigated 4-Nerolidylcatechol (4-NC), the principal bioactive compound from Piper umbellatum (capeba), a plant used in traditional Brazilian medicine. The team combined molecular docking, 100-nanosecond molecular dynamics simulations, and cell-based assays to characterize how 4-NC interacts with Derlin-1 and affects CRPC biology.
Computational modeling predicted that 4-NC inserts into Derlin-1's retrotranslocation channel, forming stable polar contacts with Arg85 and Thr88 and hydrophobic interactions with Val142, Met140, Ala152, and Leu155. In PC-3 androgen-independent prostate cancer cells, 4-NC showed concentration-dependent cytotoxicity with an IC50 of 39.2 μM, compared with 86.7 μM in non-cancerous PNT-2 prostate cells — roughly a twofold selectivity window. At sub-cytotoxic concentrations, 4-NC elevated reactive oxygen species, depleted glutathione by up to 70%, increased lipid peroxidation, and induced mitochondrial membrane depolarization. Transcriptional analysis revealed upregulation of UPR/ERAD markers ATF4, BiP, EDEM, and CHOP, and proteomics confirmed a pro-apoptotic shift at higher concentrations.
These findings are meaningful because CRPC currently has limited treatment options once tumors escape androgen receptor signaling. Targeting Derlin-1 to overwhelm an already-stressed proteostasis system is a mechanistically novel approach. 4-NC simultaneously disrupts redox balance and ER quality control, potentially hitting cancer cells through complementary mechanisms.
Caveats are significant: all data are preclinical (in silico and single cell line). The summary is based on the abstract only, and in vivo validation, pharmacokinetic studies, and broader cancer-cell panel testing are needed before any clinical relevance can be established.
Key Findings
- 4-NC binds Derlin-1's retrotranslocation channel in silico, forming stable polar and hydrophobic interactions.
- 4-NC shows roughly twofold cancer-cell selectivity: IC50 39.2 μM in PC-3 vs. 86.7 μM in normal prostate cells.
- Sub-cytotoxic 4-NC reduces cellular glutathione by up to 70% and increases oxidative stress markers in CRPC cells.
- 4-NC upregulates pro-apoptotic ER stress transcripts ATF4, BiP, EDEM, and CHOP, pushing cells toward cell death.
- Derlin-1 is identified for the first time as a molecular target of 4-NC in castration-resistant prostate cancer.
Methodology
The study combined in silico molecular docking and 100-nanosecond molecular dynamics simulations with in vitro assays in PC-3 (androgen-independent) and PNT-2 (non-neoplastic) prostate cell lines. Cytotoxicity was measured by SRB assay; redox status was assessed via ROS, glutathione, and lipid peroxidation assays; ER stress was evaluated by transcriptional profiling and proteomics.
Study Limitations
All findings are preclinical, derived from a single cancer cell line and computational models; no animal or human data are presented. The twofold selectivity window is modest and would need significant improvement for a viable therapeutic. The summary is based on the abstract only, as the full text was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: